Bone Biologics Co. (OTC:BBLG – Get Free Report)’s stock price fell 8.6% on Thursday . The company traded as low as $2.55 and last traded at $2.55. 79,228 shares changed hands during trading, a decline of 91% from the average session volume of 858,386 shares. The stock had previously closed at $2.79.
Bone Biologics Stock Down 8.6%
The business has a 50-day moving average price of $2.35 and a two-hundred day moving average price of $3.67. The company has a market capitalization of $4.58 million, a price-to-earnings ratio of -0.05 and a beta of 0.65.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
See Also
- Five stocks we like better than Bone Biologics
- Stock Dividend Cuts Happen Are You Ready?
- General Dynamics Hits New Highs: Why It Might Keep Climbing
- EV Stocks and How to Profit from Them
- Nike’s Turnaround: If the Shoe Fits, Buy It!
- How to trade using analyst ratings
- NVIDIA Breaks Out to New Highs: What Comes Next?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
